-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Sees Large Drop in Short Interest
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Sees Large Drop in Short Interest
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Rating) was the target of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 19,900 shares, a decline of 20.1% from the November 15th total of 24,900 shares. Based on an average daily volume of 20,400 shares, the short-interest ratio is currently 1.0 days. Approximately 0.1% of the company's stock are sold short.
Eledon Pharmaceuticals Price Performance
Shares of Eledon Pharmaceuticals stock traded up $0.08 during trading on Friday, hitting $2.49. 19,788 shares of the stock were exchanged, compared to its average volume of 48,222. The stock has a market cap of $34.25 million, a price-to-earnings ratio of -0.94 and a beta of 1.83. The firm's 50-day moving average price is $2.48 and its 200 day moving average price is $2.88. Eledon Pharmaceuticals has a 12-month low of $2.27 and a 12-month high of $5.14.
Get Eledon Pharmaceuticals alerts:Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.05). As a group, research analysts forecast that Eledon Pharmaceuticals will post -2.61 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in Eledon Pharmaceuticals by 1.4% in the first quarter. Vanguard Group Inc. now owns 679,243 shares of the company's stock valued at $2,676,000 after purchasing an additional 9,543 shares during the period. CM Management LLC increased its stake in Eledon Pharmaceuticals by 8.9% in the third quarter. CM Management LLC now owns 245,000 shares of the company's stock valued at $676,000 after purchasing an additional 20,000 shares during the period. Ensign Peak Advisors Inc increased its stake in Eledon Pharmaceuticals by 13.2% in the third quarter. Ensign Peak Advisors Inc now owns 87,286 shares of the company's stock valued at $241,000 after purchasing an additional 10,186 shares during the period. State Street Corp increased its stake in Eledon Pharmaceuticals by 10.5% in the first quarter. State Street Corp now owns 44,692 shares of the company's stock valued at $176,000 after purchasing an additional 4,257 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Eledon Pharmaceuticals by 74.2% during the second quarter. Renaissance Technologies LLC now owns 32,173 shares of the company's stock worth $79,000 after acquiring an additional 13,700 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.About Eledon Pharmaceuticals
(Get Rating)
Eledon Pharmaceuticals, Inc, clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes.
See Also
- Get a free copy of the StockNews.com research report on Eledon Pharmaceuticals (ELDN)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Rating) was the target of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 19,900 shares, a decline of 20.1% from the November 15th total of 24,900 shares. Based on an average daily volume of 20,400 shares, the short-interest ratio is currently 1.0 days. Approximately 0.1% of the company's stock are sold short.
艾爾頓製藥公司(納斯達克代碼：ELDN-GET評級)是空頭股數11月份大幅下跌的目標。截至11月30日，空頭股數共有19,900股，較11月15日的24,900股減少20.1%。以日均成交量20,400股計算，目前短息比為1.0天。該公司約0.1%的股票被賣空。
Eledon Pharmaceuticals Price Performance
Eledon製藥公司的價格表現
Shares of Eledon Pharmaceuticals stock traded up $0.08 during trading on Friday, hitting $2.49. 19,788 shares of the stock were exchanged, compared to its average volume of 48,222. The stock has a market cap of $34.25 million, a price-to-earnings ratio of -0.94 and a beta of 1.83. The firm's 50-day moving average price is $2.48 and its 200 day moving average price is $2.88. Eledon Pharmaceuticals has a 12-month low of $2.27 and a 12-month high of $5.14.
在週五的交易中，Eledon PharmPharmticals的股價上漲了0.08美元，達到2.49美元。該股成交量為19,788股，而平均成交量為48,222股。該股市值為3425萬美元，本益比為-0.94倍，貝塔係數為1.83。該公司的50日移動均線價格為2.48美元，200日移動均線價格為2.88美元。Eledon PharmPharmticals的12個月低點為2.27美元，12個月高位為5.14美元。
Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.05). As a group, research analysts forecast that Eledon Pharmaceuticals will post -2.61 earnings per share for the current year.
納斯達克(ELDN-GET Rating)上一次公佈季度收益是在11月14日(星期一)。該公司公佈本季度每股收益(0.73美元)，低於普遍預期的(0.68美元)(0.05美元)。研究分析師預測，作為一個整體，Eledon PharmPharmticals本年度的每股收益將為2.61美元。
Institutional Inflows and Outflows
機構資金流入和流出
About Eledon Pharmaceuticals
關於Eledon製藥公司
(Get Rating)
(獲取評級)
Eledon Pharmaceuticals, Inc, clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes.
Eledon PharmPharmticals，Inc.是一家臨床階段的生物製藥公司，專注於為患有自身免疫性疾病和肌萎縮側索硬化症(ALS)並需要器官或細胞移植的患者開發藥物。它的主要候選產品包括AT-1501，一種人源化的針對CD40配體的單抗，是一種表達在人類免疫系統T細胞表面的分子，目前正處於治療ALS的2a期臨床試驗，以及胰島細胞移植治療1型糖尿病的2期臨床試驗。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Eledon Pharmaceuticals (ELDN)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- 免費獲取StockNews.com關於Eledon製藥的研究報告(ELDN)
- MarketBeat：回顧一週12/12-12/16
- 哪兩家藍籌科技公司提高了他們的指引？
- 你應該擔心埃隆·馬斯克出售他持有的特斯拉股票嗎？
- 拖拉機庫存能否突破杯柄收購點？
- 現在不是購買Lennar的時候，但時機即將到來
Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Eledon PharmPharmticals Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Eledon PharmPharmticals和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧